Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Real World Evidence

BBCR Company News

Inventor of the PCR, Kary Mullis, Dies

August 15th, 2019 | Real World Evidence

Longer Stretch To The Finish Line for CNS Diseases

August 7th, 2019 | Real World Evidence

Cost vs. Value: Can We Have Both?

August 1st, 2019 | Real World Evidence

Could Seamless Adaptive Designs Advance Rare Disease Clinical Trial Design?

July 24th, 2019 | Real World Evidence

Gene Therapy for Rare Disorders Europe 2019 – October 15th – 17th, London

July 15th, 2019 | Real World Evidence

BBCR is Hiring! Boston Biotech Clinical Research is looking for a Full Time Associate Clinical Scientist to join our team!

June 21st, 2019 | Real World Evidence

SCIO Helps Early Stage Biotech Company Evaluation

January 24th, 2019 | Real World Evidence

A success story by BBCR Consulting: Candida Fratazzi MD was CMO at Ichorion Therapeutics in 2018

December 17th, 2018 | Real World Evidence

Welcome to BBCR’s New Website!

December 7th, 2018 | Real World Evidence
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Why Early Clinical Research Strategy Is Critical to Successful Drug Development
  • Why Rare Disease Drug Development Requires a Different Clinical Strategy
  • Why do orphan drug launches require specialized strategic planning?
  • BBCR and its consultants are dedicated to advancing innovative and repurposed treatments for orphan diseases, an area where impact is high, but the path is complex.
  • BBCR’s mission is to support domestic and international pharma, biotech, and device companies by nurturing their products’ strengths, while improving efficiency and safety. We specialize in strategy and provide early clinical research services to enable informed, timely decision-making for our clients.

RSS Nasdaq Globe Newswire

  • Asimov Joins the Genesis Mission, Using Boston University's NSF-Backed Cloud Lab to Power Lab-in-the-Loop AI Models July 24, 2026
  • MannKind Announces $50 Million Private Placement July 24, 2026
  • MannKind Announces FDA Approval of Furoscix ReadyFlowâ„¢, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease July 24, 2026
  • [Latest] Global Molybdenum 99 Market Size/Share Worth USD 8.33 Billion by 2035 at a 4.89% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) July 23, 2026
PRIVACY POLICY
  • LinkedIn

©2026 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs